Simulations Plus, Inc. (NASDAQ:SLP) Shares Purchased by HBK Sorce Advisory LLC

Posted by Defense World Staff on May 20th, 2023

HBK Sorce Advisory LLC lifted its stake in Simulations Plus, Inc. (NASDAQ:SLP – Get Rating) by 100.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 40,000 shares of the technology company’s stock after acquiring an additional 20,000 shares during the quarter. HBK Sorce Advisory LLC owned 0.20% of Simulations Plus worth $42,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale increased its stake in Simulations Plus by 136.7% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 35,500 shares of the technology company’s stock worth $1,730,000 after buying an additional 20,500 shares during the period. Quantbot Technologies LP increased its position in shares of Simulations Plus by 2,076.3% in the 3rd quarter. Quantbot Technologies LP now owns 9,075 shares of the technology company’s stock valued at $440,000 after purchasing an additional 8,658 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Simulations Plus by 68.0% in the 3rd quarter. Victory Capital Management Inc. now owns 11,639 shares of the technology company’s stock valued at $565,000 after purchasing an additional 4,711 shares during the last quarter. Raymond James & Associates purchased a new stake in shares of Simulations Plus in the 3rd quarter valued at approximately $341,000. Finally, Nisa Investment Advisors LLC increased its position in shares of Simulations Plus by 48.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 12,550 shares of the technology company’s stock valued at $459,000 after purchasing an additional 4,087 shares during the last quarter. 74.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Oppenheimer reissued an “outperform” rating and issued a $65.00 price objective on shares of Simulations Plus in a research report on Thursday, April 6th. BTIG Research initiated coverage on shares of Simulations Plus in a research report on Tuesday, May 9th. They issued a “buy” rating and a $55.00 target price on the stock. Finally, StockNews.com initiated coverage on shares of Simulations Plus in a research report on Thursday. They issued a “hold” rating on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $61.50.

Insider Activity at Simulations Plus

In other Simulations Plus news, insider John Anthony Dibella II sold 16,352 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $38.34, for a total transaction of $626,935.68. Following the completion of the transaction, the insider now directly owns 44,840 shares in the company, valued at approximately $1,719,165.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Simulations Plus news, insider John Anthony Dibella II sold 16,352 shares of the firm’s stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $38.34, for a total transaction of $626,935.68. Following the completion of the transaction, the insider now directly owns 44,840 shares in the company, valued at approximately $1,719,165.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Friday, February 24th. The shares were sold at an average price of $38.04, for a total transaction of $760,800.00. Following the transaction, the director now owns 3,915,739 shares of the company’s stock, valued at $148,954,711.56. The disclosure for this sale can be found here. Insiders sold 76,352 shares of company stock worth $3,074,336 over the last 90 days. Company insiders own 21.30% of the company’s stock.

Simulations Plus Price Performance

Shares of NASDAQ:SLP opened at $42.19 on Friday. The stock has a market cap of $843.80 million, a P/E ratio of 82.73 and a beta of 0.54. The firm has a fifty day moving average price of $42.30 and a 200 day moving average price of $40.46. Simulations Plus, Inc. has a 1-year low of $32.58 and a 1-year high of $67.59.

Simulations Plus (NASDAQ:SLP – Get Rating) last issued its quarterly earnings results on Wednesday, April 5th. The technology company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. The firm had revenue of $15.75 million during the quarter, compared to analysts’ expectations of $16.13 million. Simulations Plus had a net margin of 19.32% and a return on equity of 6.17%. Simulations Plus’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.21 EPS. Sell-side analysts expect that Simulations Plus, Inc. will post 0.66 EPS for the current fiscal year.

Simulations Plus Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 1st. Investors of record on Monday, April 24th were paid a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 0.57%. The ex-dividend date was Friday, April 21st. Simulations Plus’s dividend payout ratio (DPR) is 47.06%.

About Simulations Plus

(Get Rating)

Simulations Plus, Inc provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students.